Foresight LabsA jacket, two journeys

European UnionCLP

EU Draft CLP Amendment Aligns Six Annexes With GHS Revisions 8 To 10 And Part Of 11

The EU has notified a draft CLP amendment aligning six annexes with recent GHS revisions. WTO comments close on 16 October 2026.

Dr Steven Brennan

3 min readAI-drafted, expert reviewed

Unbranded aerosol cans and chemical containers in a modern formulation facility

The European Union notified a draft amendment to the Classification, Labelling and Packaging Regulation, Regulation (EC) No 1272/2008, on 17 August 2026. The proposal would align six CLP annexes with recent United Nations Globally Harmonized System of Classification and Labelling of Chemicals revisions.

The draft could affect hazard assessment and communication throughout chemicals and manufacturing supply chains. WTO comments close on 16 October 2026. The proposal is not yet law, and organisations should continue to follow current CLP requirements.

What The EU Draft CLP Amendment Would Change

The draft Commission Delegated Regulation would amend and correct Annexes I, III, IV, V, VI and VIII. It incorporates GHS revisions 8, 9 and 10 and partially implements revision 11 for aerosols and skin-sensitising mixtures. The technical changes cover classification criteria, hazard and precautionary statements, labelling elements and selected non-animal, in vitro or ex vivo approaches.

This is a horizontal update rather than a new list of individual harmonised substance classifications. Its practical reach could extend across industrial chemicals, coatings, detergents, adhesives, aerosols, consumer mixtures and workplace products, depending on their hazards and evidence base.

The notification is a proposal, not an adopted regulation. Current CLP rules remain in force, and organisations should not relabel products solely on the basis of the draft.

If adopted in its present form, the measure would apply 24 months after entry into force. Substances and mixtures already classified and labelled under the existing rules and placed on the market before that application date could continue to be placed on the market for a further period, up to 48 months after entry into force. Final dates will only become certain after adoption and publication.

Compared with the present position, the draft would bring EU technical criteria closer to newer GHS text while retaining CLP as the binding EU framework. The WTO consultation lets companies test whether the proposed wording creates classification, data or labelling problems.

Implications For Manufacturers And Supply Chains

Changes to generic criteria can cascade into product classifications, safety data sheets, labels, packaging specifications, poison-centre information and workplace risk assessments. Importers may need more evidence from non-EU suppliers, while formulators and laboratories may need to revisit mixture calculations or test strategies.

The long lead time reduces immediate relabelling pressure, but portfolio screening before adoption can reveal where one technical change would affect many stock-keeping units. Businesses can then consolidate testing, supplier outreach and artwork changes instead of handling each product separately near the application date.

What Organisations Should Do Now

Regulatory teams should compare the draft annexes with current classification rules, identify aerosols and skin-sensitising mixtures, and record evidence gaps. Businesses with material technical concerns can prepare targeted WTO comments by 16 October 2026. Change-control plans should remain provisional until the final delegated regulation is published.

Questions about this change

Does The EU Draft CLP Amendment Require Immediate Relabelling?

No. The measure is still a draft and existing CLP requirements continue to apply. If adopted unchanged, it would apply 24 months after entry into force, with a further transition for qualifying products already classified, labelled and placed on the market.

Which Products Should Companies Screen First?

Companies should prioritise aerosols, skin-sensitising mixtures and portfolios that depend on affected classification criteria, statements or test methods. Screening should follow hazards and formulation evidence rather than assume that only named substances or sectors are covered.

Dr Steven Brennan

CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.

More from Dr Steven Brennan

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX